Alternatives to Sonidegib If You Can't Fill Your Prescription

Sonidegib (Odomzo) is one of only a handful of FDA-approved treatments for locally advanced basal cell carcinoma (laBCC). But because it's a specialty-only drug with a complex access process, some patients face delays—or are unable to access it at all. If you're in that situation, here's a clear-eyed look at the alternatives your doctor might consider.

Always discuss these options with your oncologist or dermatologist. Treatment for laBCC is highly individualized.

Why Patients Seek Sonidegib Alternatives

There are several reasons a patient might need an alternative to Sonidegib:

Access delays — Specialty pharmacy and prior authorization processes can take weeks.

Insurance denial — Some plans may deny coverage even after PA submission.

Intolerance — Side effects like severe muscle spasms, elevated creatine kinase, or rhabdomyolysis may require discontinuing the drug.

Drug interactions — Certain medications (especially CYP3A inhibitors) may make Sonidegib unsafe.

Disease progression — Some patients develop resistance to Sonidegib over time.

Alternative 1: Vismodegib (Erivedge)

What it is: Vismodegib (brand name Erivedge) is the first-in-class hedgehog pathway inhibitor, FDA-approved in 2012—three years before Sonidegib. Like Sonidegib, it blocks the Smoothened (SMO) protein to stop BCC tumor growth.

How it compares: Vismodegib and Sonidegib have similar mechanisms and comparable efficacy in clinical trials. Experts suggest they work equally well, though vismodegib currently holds a larger market share. Vismodegib is taken as a 150 mg capsule once daily, also on an empty stomach. It carries many of the same side effects as Sonidegib, including muscle spasms, hair loss, taste changes, and fatigue.

Key difference: Vismodegib does not carry the same level of concern about rhabdomyolysis as Sonidegib. The Sonidegib label specifically calls for monitoring creatine kinase levels and warns of rhabdomyolysis multiple times; vismodegib's label does not include this warning.

Vismodegib is distributed through Genentech's specialty network and may be an option if Sonidegib is inaccessible through Sun Pharma's OdomzoCARE network.

Alternative 2: Cemiplimab (Libtayo)

What it is: Cemiplimab (brand name Libtayo) is a PD-1 immune checkpoint inhibitor made by Regeneron/Sanofi. It is FDA-approved for adults with locally advanced BCC who have progressed on or are intolerant to hedgehog inhibitors like Sonidegib or Vismodegib.

How it compares: Cemiplimab uses a completely different mechanism—it unleashes the immune system to attack cancer cells rather than directly blocking a tumor growth signal. It is given as an IV infusion every 3 weeks in an infusion center. This is a significant difference from the daily oral pill approach of Sonidegib and Vismodegib.

When it's used: Cemiplimab is typically used after a hedgehog inhibitor has failed or is not tolerated—not as a first-line alternative to Sonidegib. However, for patients who cannot tolerate or access hedgehog inhibitors, it may be an option to discuss with your oncologist.

Alternative 3: Surgery (Mohs Surgery or Wide Local Excision)

Sonidegib is indicated specifically for patients who are NOT candidates for surgery, or whose cancer recurred after surgery. However, if your situation changes—for example, the tumor shrinks enough to become operable, or a surgical option becomes available—surgery remains the gold standard for BCC treatment.

Mohs micrographic surgery, in particular, has high cure rates for BCC and is performed by specially trained Mohs surgeons, typically dermatologists with additional fellowship training.

38,004+ patients found their medications in stock

38K+

Find Sonidegib In Stock Today →

Alternative 4: Radiation Therapy

Radiation therapy is effective for BCC that cannot be surgically removed. Like surgery, Sonidegib is intended for patients who are not candidates for radiation or whose cancer has recurred after radiation. But if radiation was not previously tried and is medically appropriate, it may be an option your doctor considers.

Comparing Your Options at a Glance

Here is a quick comparison of the main options for locally advanced BCC:

Sonidegib (Odomzo): 200 mg oral capsule daily; specialty pharmacy only; SMO inhibitor

Vismodegib (Erivedge): 150 mg oral capsule daily; specialty pharmacy only; SMO inhibitor; similar efficacy

Cemiplimab (Libtayo): IV infusion every 3 weeks; after hedgehog inhibitor failure; PD-1 immunotherapy

Surgery/Mohs: Gold standard if tumor is resectable; may become available after tumor responds to drug treatment

Radiation therapy: Effective for localized BCC; option when surgery is not feasible

Skip the calls, skip the stress.

Find Sonidegib In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

How medfinder Can Help You Access Any of These Options

Whether you need Sonidegib, Vismodegib, or another BCC treatment, medfinder calls pharmacies on your behalf to find which ones can fill your prescription. This saves patients hours of time and frustration. Read more about why Sonidegib is hard to find for more context on the specialty pharmacy access challenge.

Bottom Line

If you can't access Sonidegib, you have real options. Vismodegib is the most direct alternative—same class, similar efficacy, different specialty pharmacy network. Cemiplimab is available for patients after hedgehog inhibitor failure. Surgery and radiation remain options for select patients. Work closely with your oncology care team to choose the right path based on your specific situation.